Current stage -Stage IV - Page 20 of 44 Posts on Medivizor
Navigation Menu

Current stage -Stage IV Posts on Medivizor

Looking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy

Looking for patients with advanced squamous cell non-small-cell lung cancer or head and neck squamous cell carcinoma to test a new type of immunotherapy

Posted by on Dec 20, 2017 in Lung cancer | 0 comments

In a nutshell This phase 1 trial is examining the safety and effectiveness of a new type of immunotherapy. The treatment involves genetically enhancing patients’ own immune cells to better fight advanced non-small-cell lung cancer (NSCLC) or head and neck cancer. The main outcome to be measured will be the highest safe dose of the treatment. This...

Read More

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Looking for men with castration-resistant prostate cancer to test ipatasertib plus abiraterone/prednisone

Posted by on Dec 5, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression. The details Metastatic prostate...

Read More

Looking for men with metastatic castration-resistant prostate cancer to test rucaparib

Looking for men with metastatic castration-resistant prostate cancer to test rucaparib

Posted by on Nov 29, 2017 in Prostate cancer | 0 comments

In a nutshell The aim of this trial is to determine how patients with advanced, hormone-resistant prostate cancer with evidence of a homologous recombination gene deficiency respond to rucaparib (Rubraca) treatment. The main outcome to be measured is the response to treatment, and changes to prostate-specific antigen levels (a protein present in...

Read More

Side effects of targeted therapies to treat metastatic colorectal cancer

Side effects of targeted therapies to treat metastatic colorectal cancer

Posted by on Nov 18, 2017 in Colorectal cancer | 0 comments

In a nutshell This study investigated the negative side effects of targeted therapy to treat elderly and younger metastatic (spread to other parts of the body) colorectal cancer patients. Researchers suggested that side effects were different between these patients. Some background Colorectal cancer is one of the most common cancers worldwide....

Read More

A combination of FOLFOXIRI and targeted therapy in the treatment of advanced colorectal cancer

A combination of FOLFOXIRI and targeted therapy in the treatment of advanced colorectal cancer

Posted by on Oct 17, 2017 in Colorectal cancer | 0 comments

In a nutshell This study examined the effectiveness of FOLFOXIRI combined with targeted therapy (TT) in advanced colorectal cancer. This study concluded that FOLFOXIRI plus TT was associated with better outcomes compared to other treatment combinations. Some background Chemotherapy is used to reduce symptoms and increase survival in colorectal...

Read More

Promising News in Melanoma From ASCO 2017

Promising News in Melanoma From ASCO 2017

Posted by on Sep 28, 2017 in Melanoma | 0 comments

Video information: As part of our coverage from the 2017 American Society of Clinical Oncology annual meeting, Dr. Ryan Sullivan from Massachusetts General Hospital Cancer Center and Harvard Medical School provides a positive update for melanoma patients. Dr. Sullivan shares positive news related to PD-1 inhibitors and other promising advancements...

Read More

Looking for patients with newly diagnosed symptomatic NSCLC to test durvalumab

Looking for patients with newly diagnosed symptomatic NSCLC to test durvalumab

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This phase 2 clinical trial will test the safety and effectiveness of durvalumab as a first-line therapy for non-small cell lung cancer (NSCLC). The primary outcome will be measured by overall survival and the number of patients with adverse (negative) side effects. The details Durvalumab is an immunotherapy for metastatic tumors...

Read More

Looking for patients with advanced non-small cell lung cancer to test the effectiveness of Poziotinib

Looking for patients with advanced non-small cell lung cancer to test the effectiveness of Poziotinib

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This phase 2 clinical trial will test the effectiveness of poziotinib in treating locally advanced (spread to nearby tissue) or metastatic (spread to other parts of the body) non-small cell lung cancer (NSCLC) with an EGFR mutation. The primary outcome will be measured by the response rate to the treatment. This trial is being conducted...

Read More

Looking for patients with stage 4 or recurrent non-small cell lung cancer to test the effectiveness of a combined immunotherapy with chemotherapy

Looking for patients with stage 4 or recurrent non-small cell lung cancer to test the effectiveness of a combined immunotherapy with chemotherapy

Posted by on Sep 26, 2017 in Lung cancer | 0 comments

In a nutshell This phase 3 clinical trial will test the effectiveness of nivolumab (Opdivo), nivolumab with ipilimumab (Yervoy), or nivolumab with platinum-based chemotherapy compared with chemotherapy in treating patients with advanced non-small cell lung cancer (NSCLC). The primary outcome will be measured by the overall survival rate and time...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor